


Thalidomide-O-amido-C4-NH2 hydrochloride

Cat. No.:	HY-107438A
CAS No.:	2245697-86-1
Molecular Formula:	C ₁₉ H ₂₃ ClN ₄ O ₆
Molecular Weight:	438.86
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	-20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (569.66 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>2.2786 mL</td> <td>11.3932 mL</td> <td>22.7863 mL</td> </tr> <tr> <td>5 mM</td> <td>0.4557 mL</td> <td>2.2786 mL</td> <td>4.5573 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2279 mL</td> <td>1.1393 mL</td> <td>2.2786 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	2.2786 mL	11.3932 mL	22.7863 mL	5 mM	0.4557 mL	2.2786 mL	4.5573 mL	10 mM	0.2279 mL	1.1393 mL	2.2786 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	2.2786 mL	11.3932 mL	22.7863 mL																		
	5 mM	0.4557 mL	2.2786 mL	4.5573 mL																		
	10 mM	0.2279 mL	1.1393 mL	2.2786 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.74 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.74 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.74 mM); Clear solution 																					

BIOLOGICAL ACTIVITY

Description	Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs ^[1] .
IC₅₀ & Target	Cereblon
In Vitro	Thalidomide-O-amido-C4-NH2 is an amine intermediate (Compound 41), which can be used as a heterobifunctional PROTAC BET degrader. The bromodomain and extra-terminal (BET) family proteins, consisting of BRD2, BRD3, BRD4, and testis-specific BRDT members, are epigenetic “readers” and play a key role in the regulation of gene transcription. BET

proteins are considered to be attractive therapeutic targets for cancer and other human diseases. Recently, heterobifunctional small-molecule BET degraders have been designed based upon the proteolysis targeting chimera (PROTAC) concept to induce BET protein degradation^[1]. Thalidomide-O-amido-C4-NH₂ is a degron-linker (refer to Compound DL6-TL). Degron-linker-targeting ligand, wherein the linker is covalently bound to at least one degron and at least one targeting ligand, the degron is a compound capable of binding to an ubiquitin ligase such as an E3 ubiquitin ligase (e.g., cereblon), and the targeting ligand is capable of binding to the targeted protein (s)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Zhou B, et al. Discovery of a Small-Molecule Degradator of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. *J Med Chem.* 2018 Jan 25;61(2):462-481.

[2]. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017024317 A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA